Evolus (NASDAQ:EOLS) Shares Down 2.4% - What's Next?

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) shares traded down 2.4% during trading on Monday . The stock traded as low as $12.80 and last traded at $12.72. 41,269 shares were traded during trading, a decline of 93% from the average session volume of 590,097 shares. The stock had previously closed at $13.03.

Analyst Ratings Changes

Several research analysts have recently weighed in on EOLS shares. Barclays boosted their price target on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. HC Wainwright reissued a "buy" rating and issued a $27.00 target price on shares of Evolus in a research report on Wednesday, March 5th. Finally, Needham & Company LLC restated a "buy" rating and set a $22.00 target price on shares of Evolus in a research note on Wednesday, March 5th.

Evolus Trading Down 1.0 %

The firm has a market capitalization of $770.36 million, a P/E ratio of -13.31 and a beta of 1.28. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The stock has a 50 day simple moving average of $13.63 and a 200-day simple moving average of $13.82.

Insiders Place Their Bets

In other Evolus news, insider Rui Avelar sold 27,904 shares of the company's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $370,007.04. Following the completion of the sale, the insider now owns 362,467 shares in the company, valued at $4,806,312.42. This represents a 7.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Sandra Beaver sold 8,996 shares of Evolus stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $119,286.96. Following the transaction, the chief financial officer now directly owns 173,583 shares in the company, valued at approximately $2,301,710.58. The trade was a 4.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 54,324 shares of company stock worth $716,856. Company insiders own 6.10% of the company's stock.

Remove Ads

Hedge Funds Weigh In On Evolus

Hedge funds have recently modified their holdings of the company. Tri Locum Partners LP purchased a new position in shares of Evolus during the 4th quarter valued at $8,198,000. Gilder Gagnon Howe & Co. LLC lifted its position in shares of Evolus by 287.2% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 702,239 shares of the company's stock valued at $7,753,000 after acquiring an additional 520,859 shares in the last quarter. Caligan Partners LP lifted its position in shares of Evolus by 22.7% in the fourth quarter. Caligan Partners LP now owns 2,692,388 shares of the company's stock valued at $29,724,000 after acquiring an additional 498,900 shares in the last quarter. Allostery Investments LP bought a new position in shares of Evolus in the fourth quarter worth about $4,760,000. Finally, Altium Capital Management LLC grew its position in shares of Evolus by 93.0% during the fourth quarter. Altium Capital Management LLC now owns 685,000 shares of the company's stock worth $7,562,000 after purchasing an additional 330,000 shares in the last quarter. 90.69% of the stock is currently owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.